| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
,
PHILIP H. FROST and
RALPH R. CAVALIERI
Cardiovascular Research Institute and the Department of Medicine, University of California San Francisco, California 94143
Endocrine-Metabolism Section and Nuclear Medicine Service, Veterans Administration Medical Center and University of California San Francisco, California 94121
Address all correspondence and requests for reprints to: Carl M. Mendel, M.D. Cardiovascular Research Institute M -1327 University of California, San Francisco, California 94143.
The concentration of FFA in normal human plasma in vivo generally ranges between 0.2 and 0.7 meq/liter; slightly higher concentrations have occasionally been reported in patients who are seriously ill. To determine whether such FFA concentrations may increase the concentration of free T4 in serum, we added increasing amounts of oleic acid to pooled normal human serum (with known FFA content) and measured free T4 by equilibrium dialysis. Total FFA up to 3 meq/liter in normal serum, representing an FFA to albumin molar ratio of about 5:1, had little or no effect on the free T4 concentration, while higher FFA concentrations progressively increased free T4. This same molar ratio of FFA to albumin had to be exceeded to cause a significant increase in the free T4 concentration in diluted serum and in serum from patients with nonthyroid illness. Serum from which more than 95% of the albumin had been removed by chromatography with Affi-Gel blue was much more sensitive to the effects of FFA on free T4. This enhanced sensitivity was reversed by readdition of albumin to the serum, and the addition of albumin to normal serum resulted in diminished effects of FFA on free (T)4(.) These results indicate the following: 1) physiological concentrations of FFA do not significantly increase the free T4 concentration in normal human serum; 2) when FFA reach supraphysiological concentrations in serum (in vitro) and the higher affinity FFA-binding sites on albumin become saturated (apparently at an FFA to albumin molar ratio of 5:1), the excess FFA interact with other serum proteins, including thyroid hormone-binding globulin, and thereby increase the free T4 concentration; 3) the concentration of albumin (or other FFA binders) must be considered when evaluating the observed effects of FFA.
To explore the relevance of these findings to the hypothesis that FFA may inhibit the binding of T4 to plasma proteins in patients with nonthyroid illness, we measured plasma FFA concentrations in 11 severely ill patients hospitalized in the intensive care unit. We found a mean plasma FFA concentration of 0.45 ± 0.11 (±SEM) mEq/liter and a mean serum albumin concentration of 2.39 ±0.29 g/dl in these patients. Their mean plasma FFA to albumin molar ratio was 1.53 ± 0.41. Since the FFA to albumin molar ratio must exceed about 5:1 before a significant increase in the serum free T4concentration occurs, these results suggest tha t FFA do not commonly influence the circulating free T4 concentration in vivo, even in severely ill patients.
* This work was supported by the Medical Research Service of the V.A. and Grants HL-14237 (Arteriosclerosis SCOR) and HL-01546 (Clinical Investigator).
Charles E. Culpeper Foundation Fellow
Received July 1, 1986.
This article has been cited by other articles:
![]() |
S. Peng, C. Rahner, and L. J. Rizzolo Apical and Basal Regulation of the Permeability of the Retinal Pigment Epithelium Invest. Ophthalmol. Vis. Sci., February 1, 2003; 44(2): 808 - 817. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Laji, B. Rhidha, R. John, J. Lazarus, and J.S. Davies Abnormal serum free thyroid hormone levels due to heparin administration QJM, September 1, 2001; 94(9): 471 - 473. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E.M. Midgley Direct and Indirect Free Thyroxine Assay Methods: Theory and Practice Clin. Chem., August 1, 2001; 47(8): 1353 - 1363. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J. De Groot Dangerous Dogmas in Medicine: The Nonthyroidal Illness Syndrome J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 151 - 164. [Full Text] |
||||
![]() |
I. J. Chopra Euthyroid Sick Syndrome: Is It a Misnomer? J. Clin. Endocrinol. Metab., February 1, 1997; 82(2): 329 - 334. [Full Text] [PDF] |
||||
![]() |
M. I. Surks and R. Sievert Drugs and Thyroid Function N. Engl. J. Med., December 21, 1995; 333(25): 1688 - 1694. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |